Conference Coverage

AACE 2018: A dream team of presenters


 

FROM AACE 2018

Boston is the location and inspiration for the featured presentations at the annual meeting of the American Association of Clinical Endocrinologists, program chair Vin Tangpricha, MD, PhD, said in an interview.

The program agenda for the congress, held May 16-20, boasts 143 speakers, 66 distinct clinical endocrinology educational sessions, and an opening plenary presentation featuring one of modern medicine’s most renowned diabetes and obesity researchers, according to a statement from the AACE.

Dr. Vin Tangpricha

The meeting’s theme is “Charting the Future,” an ode to Boston’s reputation for seafaring and medical innovation; Dr. Tangpricha, a professor of medicine at Emory University in Atlanta, gave a preview on how each of the following top sessions by endocrinology luminaries will enhance clinical endocrinologists’ practice.

New Dimensions in Insulin Action and Why They Are Important to Know

C. Ronald Kahn, MD, chief academic officer and head of Integrative Physiology and Metabolism at Joslin Diabetes Center in Boston, pioneered revolutionary work with insulin receptors and insulin resistance in diabetes and obesity. What makes his presentation on Thursday from 8:30 a.m. to 9:15 a.m. a must-see is its focus on the future: “Many new drugs are being developed based on the research on how insulin works. This lecture will be exciting to hear what is in the pipeline for drugs that manipulate insulin action,” Dr. Tangpricha said.

Cushing’s Syndrome

SeanPavonePhot/Thinkstock
“There have been so many new developments in the treatment of Cushing’s disease, including new medications and diagnostic tests that impact the care of Cushing’s disease today and in the future,” Dr. Tangpricha mused. Not to worry: Beverly M.K. Biller, MD, who is a professor of medicine at Harvard Medical School in Boston and has coauthored clinical guidelines on Cushing’s syndrome, will sort them out in her session on Thursday from 9:15 a.m. to 10:00 a.m.

Beta-Cell Regeneration

The work of Andrew F. Stewart, MD, scientific director of the Mount Sinai Diabetes, Obesity and Metabolism Institute in New York, leads research into the basic mechanisms, prevention, and treatment of metabolic diseases. “In the past, we thought that there was a fixed number of beta cells in the body. However, recent research by Dr. Stewart’s group suggests that beta cells can be stimulated to grow. This is very exciting and can shape the future of how we take care of diabetes,” noted Dr. Tangpricha. The session is on Friday from 8:20 a.m. to 9:05 a.m.

New Insights Into Thyroid Hormone Action

On Thursday from 11:15 a.m. to 12:00 p.m., Anthony N. Hollenberg, MD, will present “an outstanding review on thyroid hormone and action and how this impacts patient care of those with thyroid disease,” Dr. Tangpricha said. Dr. Hollenberg is chief of the thyroid unit and the division of endocrinology, diabetes, and metabolism at Beth Israel Deaconess Medical Center in Boston.

Pages

Recommended Reading

ACP issues 4 statements on T2DM treatment targets
MDedge Family Medicine
Artificial pancreas treatment improves glycemic control in T1DM: Meta-analysis
MDedge Family Medicine
MDedge Daily News: Physician burnout needs more than yoga
MDedge Family Medicine
Hormone therapy raises diabetes risk in breast cancer survivors
MDedge Family Medicine
Metabolic syndrome scoring system predicts CVD in type 2 diabetes
MDedge Family Medicine
Abstract: Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes
MDedge Family Medicine
Commentary: Shifting the care delivery paradigm to diabetes-depression collaborative care models
MDedge Family Medicine
Glyburide failed to show noninferiority in gestational diabetes
MDedge Family Medicine
Even a year of increased water intake did not change CKD course
MDedge Family Medicine
Original research expands at AACE 2018
MDedge Family Medicine